Sayaka Kuba1, Mayumi Ishida2, Yoshiaki Nakamura2, Kosho Yamanouchi3, Shigeki Minami3, Kenichi Taguchi4, Susumu Eguchi3, Shinji Ohno2. 1. Department of Breast Oncology, National Hospital Organization, Kyushu Cancer Center, Fukuoka Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki skuba@nagasaki-u.ac.jp. 2. Department of Breast Oncology, National Hospital Organization, Kyushu Cancer Center, Fukuoka. 3. Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki. 4. Department of Pathology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan.
Abstract
OBJECTIVE: How breast cancer subtypes should affect treatment decisions for breast cancer patients with brain metastases is unclear. We analyzed local brain metastases treatments and their outcomes according to subtype in patients with breast cancer and brain metastases. METHODS: We reviewed records and database information for women treated at the National Kyushu Cancer Center between 2001 and 2010. Patients were divided into three breast cancer subtype groups: Luminal (estrogen receptor positive and/or progesterone receptor positive, but human epidermal growth factor receptor 2 negative); human epidermal growth factor receptor 2 positive and triple negative (estrogen receptor negative, progesterone receptor negative and human epidermal growth factor receptor 2 negative). RESULTS: Of 524 advanced breast cancer patients, we reviewed 65 (12%) with brain metastases and records showing estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status, as well as outcome data; there were 26 (40%) Luminal, 26 (40%) had human epidermal growth factor receptor 2 and 13 (20%) had triple negative subtypes. There was no statistical difference in the number of brain metastases among subtypes; however, rates of stereotactic radiosurgery or surgery for brain metastases differed significantly by subtype (human epidermal growth factor receptor 2: 81%, Luminal: 42% and triple negative: 47%; P = 0.03). Patients having the human epidermal growth factor receptor 2 subtype, a performance status of ≤1 and ≤4 brain metastases, who underwent systemic therapy after brain metastases and underwent stereotactic radiosurgery or surgery, were predicted to have longer overall survival after brain metastases. Multivariate analysis demonstrated that not having systemic therapy and not having the human epidermal growth factor receptor 2 subtype were independent factors associated with an increased risk of death (hazard ratio 2.4, 95% confidence interval 1.01-5.6; P = 0.05 and hazard ratio 2.9, 95% confidence interval 1.5-5.8; P = 0.003, respectively). CONCLUSION: Our study showed that local brain treatments and prognosis differed by subtype in breast cancer patients with brain metastases.
OBJECTIVE: How breast cancer subtypes should affect treatment decisions for breast cancerpatients with brain metastases is unclear. We analyzed local brain metastases treatments and their outcomes according to subtype in patients with breast cancer and brain metastases. METHODS: We reviewed records and database information for women treated at the National Kyushu Cancer Center between 2001 and 2010. Patients were divided into three breast cancer subtype groups: Luminal (estrogen receptor positive and/or progesterone receptor positive, but humanepidermal growth factor receptor 2 negative); humanepidermal growth factor receptor 2 positive and triple negative (estrogen receptor negative, progesterone receptor negative and humanepidermal growth factor receptor 2 negative). RESULTS: Of 524 advanced breast cancerpatients, we reviewed 65 (12%) with brain metastases and records showing estrogen receptor, progesterone receptor and humanepidermal growth factor receptor 2 status, as well as outcome data; there were 26 (40%) Luminal, 26 (40%) had humanepidermal growth factor receptor 2 and 13 (20%) had triple negative subtypes. There was no statistical difference in the number of brain metastases among subtypes; however, rates of stereotactic radiosurgery or surgery for brain metastases differed significantly by subtype (humanepidermal growth factor receptor 2: 81%, Luminal: 42% and triple negative: 47%; P = 0.03). Patients having the humanepidermal growth factor receptor 2 subtype, a performance status of ≤1 and ≤4 brain metastases, who underwent systemic therapy after brain metastases and underwent stereotactic radiosurgery or surgery, were predicted to have longer overall survival after brain metastases. Multivariate analysis demonstrated that not having systemic therapy and not having the humanepidermal growth factor receptor 2 subtype were independent factors associated with an increased risk of death (hazard ratio 2.4, 95% confidence interval 1.01-5.6; P = 0.05 and hazard ratio 2.9, 95% confidence interval 1.5-5.8; P = 0.003, respectively). CONCLUSION: Our study showed that local brain treatments and prognosis differed by subtype in breast cancerpatients with brain metastases.
Authors: Daisuke Yamashita; Mutsuko Minata; Ahmed N Ibrahim; Shinobu Yamaguchi; Vito Coviello; Joshua D Bernstock; Shuko Harada; Richard A Cerione; Bakhos A Tannous; Concettina La Motta; Ichiro Nakano Journal: Mol Cancer Ther Date: 2020-03-03 Impact factor: 6.261
Authors: José P Leone; Bjarni Haraldsson; Sarah L Mott; Bradley D McDowell; Elizabeth A Chrischilles Journal: Am J Clin Oncol Date: 2019-01 Impact factor: 2.339
Authors: Matthew N Mills; Chetna Thawani; Nicholas B Figura; Daniel E Oliver; Aixa E Soyano; Arnold Etame; Timothy J Robinson; James K Liu; Michael A Vogelbaum; Peter A Forsyth; Brian J Czerniecki; Hatem H Soliman; Hyo S Han; Hsiang-Hsuan Michael Yu; Kamran A Ahmed Journal: J Neurooncol Date: 2021-03-19 Impact factor: 4.130
Authors: Antonio Martínez-Aranda; Vanessa Hernández; Ferran Moreno; Núria Baixeras; Daniel Cuadras; Ander Urruticoechea; Miguel Gil-Gil; Noemí Vidal; Xavier Andreu; Miquel A Seguí; Rosa Ballester; Eva Castella; Angels Sierra Journal: Front Oncol Date: 2017-12-01 Impact factor: 6.244
Authors: Allison M Martin; Daniel N Cagney; Paul J Catalano; Laura E Warren; Jennifer R Bellon; Rinaa S Punglia; Elizabeth B Claus; Eudocia Q Lee; Patrick Y Wen; Daphne A Haas-Kogan; Brian M Alexander; Nancy U Lin; Ayal A Aizer Journal: JAMA Oncol Date: 2017-08-01 Impact factor: 31.777
Authors: Sherona R Sirkisoon; Richard L Carpenter; Tadas Rimkus; Lance Miller; Linda Metheny-Barlow; Hui-Wen Lo Journal: Front Biosci (Elite Ed) Date: 2016-01-01
Authors: M E Menezes; S K Das; I Minn; L Emdad; X-Y Wang; D Sarkar; M G Pomper; P B Fisher Journal: Adv Cancer Res Date: 2016-08-17 Impact factor: 6.242